DSDevin Schoen

Devin Schoen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Devin Schoen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    White matter fractional anisotropy predicts Parkinson's disease medication changes with deep brain stimulation

    by Devin Schoen, Philip Shih, Lucia West, Skyler Deutsch, Juhi Mehta, Carleigh Williams, Sarah Wang, Doris D. Wang, Jill L. Ostrem, Ian O. Bledsoe, et al.

  • Open Access

    Boundary complexity of cortical and subcortical areas predicts deep brain stimulation outcomes in Parkinson’s disease

    by Devin Schoen, Skyler Deutsch, Juhi Mehta, Sarah Wang, John Kornak, Philip A. Starr, Doris D. Wang, Jill L. Ostrem, Ian O. Bledsoe, Melanie A. Morrison

    While deep brain stimulation (DBS) remains an effective therapy for Parkinson’s disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here, we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical brain. FD was validated as a biomarker of PD progression through comparison of patients with PD and healthy controls (HCs). This analysis revealed significant group differences in FD across nine brain regions, including frontal, occipital, insular, and basal ganglia areas, which supports its utility as a marker of PD. We evaluated the impact of adding imaging features (FD) to a clinical model that included demographics and clinical parameters (age, sex, total number and location of DBS electrodes), and preoperative motor response to levodopa. This model aimed to explain variance and predict changes in medication following DBS. Regression analysis revealed that inclusion of the FD of distributed brain areas correlated with post-DBS reductions in medication burden, explaining an additional 13.6% of outcome variance (R2 = 0.388) compared to clinical features alone (R2 = 0.252). Hypergraph-based classification learning tasks achieved an area under the receiver operating characteristic curve of 0.64 when predicting with clinical features alone, versus 0.76 when combining clinical and imaging features. These findings demonstrate that PD effects on brain morphology linked to disease progression influence DBS outcomes. The work also highlights FD as a potentially useful imaging biomarker to enhance DBS candidate selection criteria for optimized treatment planning.


  • Open Access

    Boundary Complexity of (Sub-) Cortical Areas Predict Deep Brain Stimulation Outcomes in Parkinson’s Disease

    by Devin Schoen, Skyler Deutsch, Juhi Mehta, Sarah Wang, John Kornak, Philip Starr, Doris Wang, Jill Ostrem, Ian Bledsoe, Melanie Morrison

    While deep brain stimulation (DBS) remains an effective therapy for Parkinson’s disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical areas. FD was validated as a biomarker of Parkinson's disease (PD) progression through comparison of patients with PD and healthy controls (HCs). This analysis revealed significant group differences in FD across nine brain regions which supports its utility as a marker of PD. We evaluated the impact of adding imaging features (FD) to a clinical model that included demographics and clinical parameters—age, sex, total number and location of DBS electrodes, and preoperative motor response to levodopa. This model aimed to explain variance and predict changes in medication following DBS. Regression analysis revealed that inclusion of the FD of distributed brain areas correlated with post-DBS reductions in medication burden, explaining an additional 13.6% of outcome variance (R2=0.388) compared to clinical features alone (R2=0.252). Hypergraph-based classification learning tasks achieved an area under the receiver operating characteristic curve of 0.64 when predicting with clinical features alone, versus 0.76 when combining clinical and imaging features. These findings demonstrate that PD effects on brain morphology linked to disease progression influence DBS outcomes. The work also highlights FD as a potentially useful imaging biomarker to enhance DBS candidate selection criteria for optimized treatment planning.

  • Top Cited Papers
    Open Access

    Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

    by Timothy A. Bates, Savannah K. McBride, Hans C. Leier, Gaelen Guzman, Zoe L. Lyski, Devin Schoen, Bradie Winders, Joon-Yong Lee, David Xthona Lee, William B. Messer, et al.

    Current coronavirus disease 2019 (COVID-19) vaccines effectively reduce overall morbidity and mortality and are vitally important to controlling the pandemic. Individuals who previously recovered from COVID-19 have enhanced immune responses after vaccination (hybrid immunity) compared with their naïve-vaccinated peers; however, the effects of post-vaccination breakthrough infections on humoral immune response remain to be determined. Here, we measure neutralizing antibody responses from 104 vaccinated individuals, including those with breakthrough infections, hybrid immunity, and no infection history. We find that human immune sera after breakthrough infection and vaccination after natural infection broadly neutralize SARS-CoV-2 (severe acute respiratory coronavirus 2) variants to a similar degree. Although age negatively correlates with antibody response after vaccination alone, no correlation with age was found in breakthrough or hybrid immune groups. Together, our data suggest that the additional antigen exposure from natural infection substantially boosts the quantity, quality, and breadth of humoral immune response regardless of whether it occurs before or after vaccination.